 |
|
|
| |
Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Participants (BRIGHTE Study)
|
| |
| |
I Reported IBALIZUMAB the poster at Glasgow, for those who need another new drug to attain full viral suppression Fostemsavir is in the pipeline.
By Jules Levin
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
J. Aberg,1J.-M. Molina,2M. Kozal,3P. Cahn,4J. Lalezari,5M. Thompson,6R. Diaz,7A. Castagna,8G. Pialoux,9M. Gummel,10A. Pierce,11P. Ackerman,12 C. Llamoso,12M. Lataillade12
1Icahn School of Medicine at Mount Sinai, New York, NY, USA2Hopital Saint-Louis, APHP and University of Paris Diderot Paris, Infectious Diseases, Paris, France; 3Yale University School of Medicine, New Haven, CT, USA; 4Fundación Huesped, Buenos Aires, Argentina; 5Quest Clinical Research, San Francisco, CA, USA; 6AIDS Research Consortium of Atlanta, GA, USA; 7The Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; 8Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Milan, Italy; 9Hopital Tenon, Paris, France; 10GlaxoSmithKline, Upper Providence, Philadelphia, PA, USA; 11ViiV Healthcare, Research Triangle Park, NC, USA; 12ViiV Healthcare, Branford, CT, USA
|
| |
|
|
|
|
|
